查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832360

牛呼吸道疾病治疗市场（依产品类型、给药途径、动物类型和通路）－2025-2032 年全球预测

Bovine Respiratory Disease Treatment Market by Product Type, Route Of Administration, Animal Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，牛呼吸道疾病治疗市场将成长至 38.4 亿美元，复合年增长率为 7.80%。

主要市场统计数据
基准年2024年 21亿美元
预计2025年 22.7亿美元
预测年份：2032年 38.4亿美元
复合年增长率（%） 7.80%

牛呼吸道疾病治疗的策略方法使治疗选择与临床现实、监管趋势和业务重点保持一致。

牛呼吸道疾病仍是全球畜牧生产系统中最持久且经济影响最大的健康挑战之一。本出版物将读者置于临床、药物开发和供应链演变的交汇点，重点关注临床驱动因素、监管压力和生产经济因素如何影响治疗策略。疾病本身包含病毒和细菌病因，通常需要综合治疗和预防，而抗生素和疫苗的相互作用是有效控制计画的关键。

临床医生和牛管理者越来越依赖实证通讯协定，以平衡动物福利、抗菌药物管理和营运效率。在此背景下，治疗方法选择受到病原体流行情况、动物类别、给药途径的适宜性以及分销管道的可及性的影响。此外，监管变化和对减少抗菌药物使用的日益重视使情况更加复杂，从而增强了有针对性的疫苗接种计划和替代给药方法的作用。

因此，本出版物将围绕四大支柱组装后续分析：治疗方式和剂型、给药途径和农场物流、动物人口统计考量以及分销生态系统。透过围绕这些支柱展开讨论，读者将获得实用指导，以支援产品开发、临床实施和商业规划方面的策略决策。

科学创新、不断发展的管理方法和分布重新配置如何重塑治疗策略和临床实践范式

由于科学创新、监管调整和生产方法的改变，牛呼吸道疾病的治疗格局正在发生重大变化。疫苗技术和製剂科学的进步使得预防主要病毒和细菌的多种选择成为可能，包括灭活疫苗和减毒活病毒疫苗。同时，抗生素种类和给药策略的改进正在推进抗菌药物管理的目标，同时又不牺牲临床患病动物的治疗效果。

同样重要的是给药方法的改变。虽然肠外给药仍然是快速全身治疗的主要方式，但经鼻吸入型疫苗和透过饲料或水口服给药由于易于批量给药和减少操作压力，正获得实际支持。这些变化与牲畜人口统计相关。成年牛和幼牛（例如肉牛和酪农）的治疗方案差异很大，成年牛需要不同的管理考虑，而幼牛的免疫成熟度和管理系统会影响预防和治疗的时间。

分销系统也在同步发展。传统兽医管道仍在提供临床监督和处方笺治疗，而商业性和农场饲料厂以及线上动物保健平台正在重塑获取和采购行为。这些趋势共同迫使产品开发商和供应商重塑市场策略，并促进製药、饲料和兽医服务供应商之间建立新的联盟。

近期关税政策更新对供应链、采购实践以及获得牛健康必需治疗的连续性的实际影响

美国2025年关税议程的进展正在影响整个动物用药品生态系统的供应链决策、采购策略和成本结构。进口关税和海关通讯协定的变化正在影响成品药品、疫苗成分和活性成分的分销，迫使製造商和经销商重新评估筹资策略和库存配置，以保持供应的连续性。拥有复杂全球供应链的公司被迫评估近岸外包、双重采购和策略性储备，以作为应对关税衝击的缓解策略。

这些转变将对从饲料厂运营商到兽医诊所等相关人员产生下游影响。采购药物预混料的饲料预混合料和采购治疗药物的农场工厂现在面临到岸成本的变化，这可能会影响透过饲料或水给药的口服药物的定价和供应。同样，线上动物用药品平台和进口利基配方的一般电子零售商可能会调整其产品目录，以应对利润压力和合规复杂性。对于动物生产者而言，实际影响是需要重新关注预防措施，例如进行疫苗宣传活动以减少对进口治疗药物的依赖，并密切注意采购时间表和供应商的可靠性。

监管协调和贸易便利化措施仍是关键变数。在关税变化造成摩擦的情况下，诸如集中采购、供应商多元化和本地配方开发等行业协作应对措施正在成为切实可行的应对措施。这些应对措施优先考虑持续获得基本治疗和疫苗，同时确保遵守临床方案和管理职责。

将治疗类别、给药途径、动物统计数据和分销管道与临床和商业策略联繫起来的详细细分观点

细分洞察揭示了不同产品类别、给药途径、动物类型和分销管道的差异化商业机会和临床考虑。依产品类型划分，抗生素涵盖药理学上不同的类别，例如β-内酰胺类、Fluoroquinolones、大环内酯类和四环霉素，其中大环内酯类的代表药物包括替米考星、泰拉霉素和泰乐菌素。疫苗具有预防作用，分为牛呼吸道融合细胞病毒、巴氏桿菌和副流感病毒3型等病原体的灭活疫苗，以及针对牛呼吸道合胞病毒、曼氏桿菌和PI3型等病原体的减毒活病毒疫苗。

给药途径是关键的细分视角。当需要全身浓度和快速起效时，肌肉注射、静脉注射或皮下注射仍然是标准。另一方面，透过饲料或饮水给药的口服製剂可以实现大剂量给药策略并减少操作，但需要谨慎给药并考虑偏好。牛（包括肉牛和乳牛）与牛和小母牛相比，有不同的生产目标和管理限制，免疫能力和管理系统的脆弱性会影响给药时机和方案选择。肉牛和牛酪农系统中的牛可能需要更早针对每牛采取预防性干预措施和治疗方法。

分销通路细分强调服务和物流方面。饲料厂（商业和农场）在供应药物饲料和支持口服给药策略方面发挥重要作用。线上药局充当动物保健平台和通用电子零售管道，在法律规范允许的情况下扩大产品获取管道。从独立诊所到大型多设施集团的兽医院继续提供临床监督、诊断和处方笺治疗。了解这些相互交叉的细分市场，有助于相关人员将产品开发、包装、低温运输设计和商业模式与最终用户需求和营运实际情况相结合。

当地生产系统、法规环境和分销基础设施如何影响差异化治疗方式和部署策略

美洲、欧洲、中东和非洲以及亚太地区的区域动态决定了临床重点、监管预期和分销策略。在美洲，从大型商业饲养场到家庭经营的酪农，各种生产系统意味着多样化的治疗需求，因此管理计划和可追溯性至关重要。疫苗宣传活动和有针对性的抗生素治疗方案透过兽医网络和一体化供应链进行协调，饲料厂和兽医诊所在产品分销中发挥关键作用。

在欧洲、中东和非洲，法律规范和管理倡议通常鼓励保守使用抗生素并更多地采用预防策略。该地区展现出一系列基础设施能力，从欧洲部分地区高度发达的低温运输系统到部分中东和北非市场较为分散的分销网络，影响了减毒活病毒疫苗和注射剂的实用化。亚太地区的特点是集约化生产系统的快速成长、多样化的法规环境以及线上动物用药品平台和商业饲料厂的作用不断扩大。在许多亚太市场，生产规模和与製造地的接近性创造了独特的物流优势和挑战，尤其是对于透过饲料或水进行治疗而言。

在整个全部区域，对相关人员的实际影响包括：使产品形式与物流现实一致，考虑监管和管理框架，并根据当地采购实践调整商业性方法。因此，跨区域知识转移和适应性实施策略对于成功开展治疗和预防计画至关重要。

企业策略响应强调配方创新、通路伙伴关係和诊断集成，以应对临床需求和供应链挑战

主要企业洞察凸显了产业参与者如何应对临床需求、供应链复杂性和不断变化的分销模式。领先的开发商和供应商正在投资製剂创新，包括优化稳定性、减少对低温运输的依赖，以及扩展口服和鼻腔给药方案以支持更大剂量给药。其他公司也在改进其註射剂产品组合，以改善药物动力学特征和给药便利性，同时继续支持符合管理规范的指导方针和标籤优化。

製药公司、饲料生产商和兽医服务供应商之间的合作，能够打造将治疗产品与农场配送能力结合的一体化解决方案。拥有多元化分销网络（包括与商业和农场饲料厂运营商、线上动物保健平台以及独立和大型兽医诊所建立合作关係）的公司，能够更好地管理特定管道的需求和监管差异。此外，面临关税和供应连续性挑战的製造商正在探索区域和製造外包安排，以缩短供应链并提高应对力。

整合诊断支援和产品交付的公司能够帮助临床医生提供标靶治疗，并衡量介入措施的效果。商业性，将治疗广度、配送灵活性和诊断有效性相结合的公司能够透过为生产商和兽医提供临床价值和营运效率，从而脱颖而出。

为製造商和经销商提供实际有效的措施，以加强管理、供应链弹性以及治疗和疫苗的农场可用性

针对产业领导者的可行建议重点在于使产品系列与管理目标保持一致，增强供应链韧性，并提升终端使用者的可及性。优先制定平衡治疗方案与预防平台的组合策略，投资于降低发病率的疫苗技术以及支持符合管理要求的抗生素使用的製剂。同时，扩大给药方式的开发，例如鼻腔给药和口服饲料/饮水给药，以减轻操作负担，并促进在牛层面的干预。

从营运角度来看，我们将在可行的情况下推行供应链多元化和近岸外包，以减轻关税的影响，并确保关键原材料和最终产品的持续供应。我们将加强与饲料厂、线上动物保健平台和兽医网路的伙伴关係，创造能够反映生产商实际获取治疗药物和疫苗方式的一体化采购路径。我们将投资于需要更严格温度控制的减毒活病毒疫苗的低温运输优化，并考虑加强剂稳定性，以减少对复杂物流的依赖。

在商业性，我们将为兽医和生产者开发教育和管理项目，强调以诊断主导的治疗、合理的途径选择以及针对牛、牛和牛的年龄和生产特定通讯协定。我们将利用诊断工具和数据分析来展示干预效果，并设计定价和获取模式，以支持小型和大型农场主，从而最大限度地提高采用率和临床效果。

采用严格的多源研究途径，结合领先的临床医师访谈、供应链映射和文献综合，提供可行的临床和商业性见解

本报告所采用的调查方法结合了多源证据整合、专家咨询和情境分析，以确保研究的稳健性和实务相关性。主要输入包括与临床医生、牛卫生专业人员、饲料厂经理和分销主管进行结构化访谈，以了解现场实践和采购行为。这些定性见解与疫苗平台、抗生素类别和剂量科学的技术文献进行了三角检验，以确保临床严谨性并阐明其操作意义。

二级资讯来源包括同行评审期刊、监管指南文件以及公开的行业报告，这些报告阐明了治疗机制、管理框架和物流考虑。调查方法也运用供应链图谱来了解活性药物成分、製剂成分和成品的采购路径，从而识别潜在的瓶颈并制定应对关税变化的适应策略。分析架构强调转化相关性，着重于产品开发、分销策略和临床实施的可行洞察，而非定量的市场预测。

透过研究过程，我们将临床医生的观点与兽医实践指南相匹配，并从分销管道的相关人员那里获得反馈，检验了我们的研究结果能够反映现实世界的限制和机会。

简明摘要强调供应链适应性是整体预防、管理主导治疗方法和永续疾病管理的基础

总而言之，有效管理牛呼吸道疾病需要整合策略，将治疗方法创新、给药实用性和弹性分销模式融为一体。疫苗技术和製剂科学的进步提供了有效的预防选择，而先进的抗生素策略和管理实践则能维持临床病例的治疗效果。给药途径的选择必须考虑农场实践、个别动物因素（例如成年牛、牛和牛）以及现有分销管道的限制。

供应链动态，包括关税调整的影响，凸显了多元化和区域适应性的重要性。将产品设计与物流能力（例如注射剂、鼻腔给药製剂以及口服饲料和饮水给药）相结合的公司，将更有能力为来自不同地区的兽医和生产商提供支援。最后，药品开发商、饲料供应商、诊断供应商和兽医网路之间的合作对于提供临床合理、操作可行且与管理相符的解决方案至关重要，这些解决方案可以改善牛健康状况并维持长期治疗效果。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合长效抗生素降低BRD復发率
  • 制定精准抗生素管理通讯协定以抑制BRD抗药性
  • 采用新型免疫调节剂增强牛对呼吸道病原体的天然防御能力
  • 利用数位生物监测和人工智慧分析及早发现生物资源短缺 (BRD) 疫情
  • 针对牛呼吸道微生物群平衡的饲料添加剂输送系统的研究进展
  • 基因编辑技术的出现增强了牛对呼吸道疾病的抵抗力

第六章 2025年美国关税的累积影响

第七章 人工智慧的累积影响，2025年

第八章牛呼吸道疾病治疗市场（依产品类型）

  • 抗生素
    • β-内酰胺类
    • Fluoroquinolones
    • 大环内酯类
      • 替米考星
      • 妥拉霉素
      • 泰乐菌素
    • 四环霉素
  • 疫苗
    • 惰性
      • BRSV
      • 巴氏桿菌
      • PI3
    • 活病毒疫苗
      • BRSV
      • 曼海姆亚属
      • PI3

第九牛依给药途径分類的牛呼吸道疾病治疗市场

  • 注射
    • 肌肉注射
    • 静脉
    • 皮下
  • 鼻内
  • 口服
    • 餵食
    • 水

第十章牛呼吸道疾病治疗市场（依动物类型）

  • 牛
    • 肉牛
    • 乳牛
  • 牛
    • 肉牛牛
    • 乳牛牛
  • 乳牛

第 11 章。牛呼吸道疾病治疗市场（按通路）

  • 饲料厂
    • 商业工厂
    • 农场工厂
  • 网路药局
    • 动物医疗平台
    • 一般零售
  • 兽医诊所
    • 独立诊所
    • 大型诊所

第十二章牛呼吸道疾病治疗市场：按地区

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章牛隻呼吸道疾病治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

牛呼吸道疾病治疗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Zoetis Inc.
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • Elanco Animal Health Incorporated
    • Ceva Sante Animale SA
    • Virbac SA
    • Phibro Animal Health Corporation
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Bimeda Inc.
Product Code: MRR-437D4595869F

The Bovine Respiratory Disease Treatment Market is projected to grow by USD 3.84 billion at a CAGR of 7.80% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.10 billion
Estimated Year [2025] USD 2.27 billion
Forecast Year [2032] USD 3.84 billion
CAGR (%) 7.80%

A strategic orientation to bovine respiratory disease treatment that aligns therapeutic choices with clinical realities, regulatory dynamics, and operational priorities

Bovine respiratory disease remains one of the most persistent and economically significant health challenges in cattle production systems globally. This introduction situates the reader at the intersection of clinical practice, pharmaceutical development, and supply chain evolution, highlighting how clinical drivers, regulatory pressures, and production economics collectively shape treatment strategies. The disease complex itself encompasses viral and bacterial etiologies that frequently require integrated therapeutic and preventive responses, and the interplay between antibiotics and vaccines is central to any effective control program.

Clinicians and herd managers increasingly rely on evidence-based protocols that balance animal welfare, antimicrobial stewardship, and operational efficiency. In this context, treatment selection is influenced by pathogen prevalence, animal category, route of administration suitability, and distribution channel accessibility. The landscape has been further complicated by shifting regulations and growing emphasis on reduced antimicrobial use, which amplifies the role of targeted vaccination programs and alternative delivery modalities.

This introduction therefore frames the subsequent analysis around four core dimensions: therapeutic modalities and formulations, administration routes and on-farm logistics, animal demographic considerations, and distribution ecosystems. By grounding the discussion in these pillars, readers will gain a practical orientation that supports strategic decisions in product development, clinical implementation, and commercial planning.

How scientific innovation, evolving administration methods, and distribution reconfiguration are reshaping treatment strategies and clinical practice paradigms

The treatment landscape for bovine respiratory disease is undergoing transformative shifts driven by scientific innovation, regulatory recalibration, and changing production practices. Advances in vaccine technology and formulation science are enabling broader preventive options, with inactivated and live attenuated platforms tailored to protect against core viral and bacterial agents. At the same time, refinement of antibiotic classes and dosing strategies is advancing antimicrobial stewardship objectives without sacrificing therapeutic potency for clinically ill animals.

Equally consequential are shifts in administration practices. Injectable delivery remains central to rapid systemic therapy, but intranasal vaccines and oral delivery via feed or water are gaining practical traction because they simplify mass administration and reduce handling stress. These changes intersect with animal demographics: protocols differ substantively between adult cattle populations, which include distinct beef and dairy management considerations, and younger cohorts such as beef calves and dairy calves where immune maturity and management systems affect both prevention and treatment timing.

Distribution systems are evolving in parallel. Traditional veterinary clinic channels continue to deliver clinical oversight and prescription-based treatments, yet feed mills-both commercial and onfarm-and online animal health platforms are reshaping access and procurement behaviors. Together, these trends are reconfiguring go-to-market strategies for product developers and suppliers, prompting new partnerships across pharmaceutical, feed, and veterinary service providers.

The practical ramifications of recent tariff policy updates on supply chains, procurement practices, and continuity of access for essential therapies in cattle health

Tariff policy developments in the United States for 2025 have influenced supply chain decisions, procurement tactics, and cost structures across the animal health ecosystem. Changes to import duties and customs protocols affect the flow of finished pharmaceuticals, vaccine components, and active ingredients, prompting manufacturers and distributors to reassess sourcing strategies and inventory positioning to preserve continuity of supply. Firms with complex global supply chains have been compelled to evaluate nearshoring, dual-sourcing, and strategic stockpiling as mitigants against tariff-driven disruptions.

These shifts have downstream effects on stakeholders from feed mill operators to veterinary clinics. Feed mills sourcing medicated premixes and onfarm mills procuring therapeutics now face altered landed costs that can impact the pricing and availability of oral medications administered via feed or water. Similarly, online animal health platforms and general eRetailers importing niche formulations may adjust catalog offerings to manage margin pressures or compliance complexity. For animal producers, the practical implication is increased attention to procurement timelines and supplier reliability, as well as a renewed focus on preventive measures such as vaccination campaigns that reduce reliance on imported therapeutic products.

Regulatory harmonization and trade facilitation efforts remain important variables. Where tariff changes create friction, collaborative industry responses-such as pooled procurement, supplier diversification, and local formulation development-are emerging as pragmatic adaptations. These responses prioritize uninterrupted access to essential therapies and vaccines while maintaining adherence to clinical protocols and stewardship commitments.

An in-depth segmentation perspective linking therapeutic categories, administration routes, animal demographics, and distribution pathways to clinical and commercial strategies

Segmentation insights reveal differentiated opportunities and clinical considerations across product classes, administration routes, animal types, and distribution pathways. Within product type, antibiotics encompass distinct pharmacological families including beta lactams, fluoroquinolones, macrolides, and tetracyclines, with macrolides further represented by agents such as tilmicosin, tulathromycin, and tylosin. Vaccines occupy preventive space and are stratified into inactivated platforms targeting pathogens like bovine respiratory syncytial virus, Pasteurella and parainfluenza 3, and live attenuated formulations that also target BRSV, Mannheimia, and PI3, each with different immunogenic profiles and cold-chain implications.

Route of administration is a pivotal segmentation lens: injectable therapies are administered intramuscularly, intravenously or subcutaneously and remain the standard when systemic concentrations and rapid onset are required. Intranasal delivery offers localized immune priming especially valuable in young stock, while oral routes administered through feed or water enable mass medication strategies that reduce handling but require careful dosing control and palatability considerations. Animal type further differentiates clinical protocols; adult cattle populations, encompassing both beef and dairy cattle, have distinct production objectives and stewardship constraints compared with calves and heifers where immune competence and management system vulnerability influence timing and regimen selection. Calves in beef and dairy systems may necessitate earlier preventive interventions and tailored therapeutic approaches.

Distribution channel segmentation highlights the service and logistics dimension. Feed mills-both commercial and onfarm-play a role in delivering medicated feeds and supporting oral administration strategies. Online pharmacies operate as animal health platforms and generalized eRetail channels, broadening access to products where regulatory frameworks permit. Veterinary clinics, from independent practices to large multi-site groups, continue to provide clinical oversight, diagnostics, and prescription-based therapies. Understanding these intersecting segments enables stakeholders to align product development, packaging, cold-chain design, and commercial models with end-user requirements and operational realities.

How regional production systems, regulatory environments, and distribution infrastructures are shaping differentiated treatment approaches and deployment strategies

Regional dynamics shape clinical priorities, regulatory expectations, and distribution strategies across the Americas, Europe, Middle East & Africa, and the Asia-Pacific. In the Americas, production systems span large-scale commercial feedlots to family-run dairy operations, yielding diverse treatment needs and a strong emphasis on stewardship programs and traceability. Vaccination campaigns and targeted antibiotic regimens are coordinated through veterinary networks and integrated supply chains, with feed mills and veterinary clinics playing prominent roles in product distribution.

Within Europe, Middle East & Africa, regulatory frameworks and stewardship initiatives often drive conservative antibiotic use and increased adoption of preventive strategies. This region demonstrates variable infrastructure capacity, from highly developed cold-chain systems in parts of Europe to more fragmented distribution networks in some Middle Eastern and African markets, which influences the practical adoption of live attenuated vaccines and injectable formulations. The Asia-Pacific region is characterized by rapid growth in intensive production systems, diverse regulatory environments, and an expanding role for online animal health platforms and commercial feed mills. In many Asia-Pacific markets, the scale of production and proximity to manufacturing hubs create unique logistics advantages and challenges, particularly around feed- and water-administered therapies.

Across regions, the practical implications for stakeholders include alignment of product formats with logistical realities, sensitivity to regulatory and stewardship frameworks, and tailoring of commercial approaches to local procurement behaviors. Cross-regional knowledge transfer and adaptive implementation strategies are therefore essential for successful deployment of therapeutics and preventive programs.

Strategic corporate responses highlighting formulation innovation, channel partnerships, and diagnostic integration to meet clinical needs and supply chain challenges

Key company insights emphasize how industry participants are responding to clinical demands, supply chain complexity, and shifting distribution models. Leading developers and suppliers are investing in formulation innovation to optimize stability, reduce cold-chain dependency, and expand oral and intranasal options that facilitate mass administration. Others are refining injectable portfolios to improve pharmacokinetic profiles and dosing convenience, while continuing to support stewardship-aligned guidance and label optimization.

Strategic partnerships are increasingly important; collaborations between pharmaceutical firms, feed producers, and veterinary service providers enable integrated solutions that align therapeutic products with onfarm delivery capabilities. Companies with diversified distribution networks, including relationships with commercial and onfarm feed mill operators, online animal health platforms, and both independent and large veterinary practices, are better positioned to manage channel-specific demands and regulatory nuances. Additionally, manufacturers addressing tariff and supply continuity challenges are exploring regional manufacturing and contract manufacturing arrangements to shorten supply lines and enhance responsiveness.

innovation in diagnostics and data-driven health management is another focal area, as companies that integrate diagnostic support with product offerings help clinicians implement targeted therapies and measure intervention outcomes. The commercial implication is that companies combining therapeutic breadth, distribution agility, and diagnostic enablement can differentiate by delivering both clinical value and operational efficiencies to producers and veterinarians.

Practical, high-impact steps for manufacturers and distributors to strengthen stewardship, supply chain resilience, and on-farm accessibility of treatments and vaccines

Actionable recommendations for industry leaders focus on aligning product portfolios with stewardship goals, strengthening supply chain resilience, and enhancing end-user accessibility. Prioritize portfolio strategies that balance therapeutic options and preventive platforms, investing in vaccine technologies that reduce disease incidence and in formulations that support stewardship-compliant antibiotic use. Simultaneously, expand development into administration modalities such as intranasal and oral feed or water delivery to lower handling burdens and facilitate herd-level interventions.

Operationally, pursue supply chain diversification and nearshoring where feasible to mitigate tariff exposure and ensure uninterrupted access to critical raw materials and finished products. Strengthen partnerships with feed mills, online animal health platforms, and veterinary networks to create integrated procurement pathways that reflect how producers obtain therapeutics and vaccines in practice. Invest in cold-chain optimization where live attenuated vaccines demand stricter temperature control, while exploring formulation stability enhancements that reduce dependency on complex logistics.

Commercially, develop education and stewardship programs aimed at veterinarians and producers that emphasize diagnostic-led treatment, appropriate route selection, and age- and production-specific protocols for adult cattle, calves, and heifers. Leverage diagnostic tools and data analytics to demonstrate intervention outcomes, and design pricing and access models that support both smallholder and large-scale operations to maximize adoption and clinical impact.

A rigorous, multi-source research approach combining frontline clinician interviews, supply chain mapping, and literature synthesis to produce actionable clinical and commercial insights

The research methodology underpinning this report integrates multi-source evidence synthesis, expert consultation, and scenario-based analysis to ensure robustness and practical relevance. Primary inputs included structured interviews with clinicians, herd health specialists, feed mill managers, and distribution executives to capture frontline practices and procurement behaviors. These qualitative insights were triangulated with technical literature on vaccine platforms, antibiotic classes, and administration science to ensure clinical accuracy and to contextualize operational implications.

Secondary sources comprised peer-reviewed journals, regulatory guidance documents, and publicly available industry reports that elucidate therapeutic mechanisms, stewardship frameworks, and logistics considerations. The methodology also applied supply chain mapping to understand sourcing pathways for active pharmaceutical ingredients, formulation components, and finished goods, allowing identification of potential chokepoints and adaptive strategies in response to tariff changes. Analytical frameworks emphasized translational relevance, focusing on actionable insights for product development, distribution strategy, and clinical implementation rather than quantitative market projections.

Throughout the research process, findings were validated by cross-checking clinician perspectives against veterinary practice guidelines and by obtaining feedback from distribution channel stakeholders to ensure that recommendations reflect real-world constraints and opportunities.

A concise synthesis emphasizing integrated prevention, stewardship-led therapeutics, and supply chain adaptability as the foundation for durable disease control

In conclusion, effective management of bovine respiratory disease requires integrated strategies that bridge therapeutic innovation, administration practicality, and resilient distribution models. Advancements in vaccine technology and formulation science provide meaningful preventive options, while refined antibiotic strategies and stewardship practices preserve therapeutic effectiveness for clinical cases. The choice of administration route must reflect operational realities on farm, individual animal factors such as adult cattle, calves, and heifers, and the constraints of available distribution channels.

Supply chain dynamics, including the implications of tariff adjustments, underscore the importance of diversification and regional adaptability. Companies that align product design with logistical capabilities-such as injectable formats, intranasal options, and oral feed- and water-administered therapies-will be better positioned to support veterinarians and producers across varied regional contexts. Finally, collaboration across pharmaceutical developers, feed suppliers, diagnostic providers, and veterinary networks is essential to deliver clinically sound, operationally feasible, and stewardship-aligned solutions that improve herd health outcomes and sustain long-term therapeutic efficacy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of long-acting antibiotic formulations to reduce BRD relapse rates
  • 5.2. Development of precision antimicrobial stewardship protocols to curb BRD resistance
  • 5.3. Adoption of novel immunomodulators enhancing bovine innate defenses against respiratory pathogens
  • 5.4. Utilization of digital biosurveillance and AI analytics for early detection of BRD outbreaks
  • 5.5. Advances in feed additive delivery systems targeting respiratory microbiome balance in cattle
  • 5.6. Emergence of gene-editing techniques to enhance bovine resistance to respiratory disease challenges

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bovine Respiratory Disease Treatment Market, by Product Type

  • 8.1. Antibiotics
    • 8.1.1. Beta Lactams
    • 8.1.2. Fluoroquinolones
    • 8.1.3. Macrolides
      • 8.1.3.1. Tilmicosin
      • 8.1.3.2. Tulathromycin
      • 8.1.3.3. Tylosin
    • 8.1.4. Tetracyclines
  • 8.2. Vaccines
    • 8.2.1. Inactivated
      • 8.2.1.1. BRSV
      • 8.2.1.2. Pasteurella
      • 8.2.1.3. PI3
    • 8.2.2. Live Attenuated
      • 8.2.2.1. BRSV
      • 8.2.2.2. Mannheimia
      • 8.2.2.3. PI3

9. Bovine Respiratory Disease Treatment Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Intranasal
  • 9.3. Oral
    • 9.3.1. Feed
    • 9.3.2. Water

10. Bovine Respiratory Disease Treatment Market, by Animal Type

  • 10.1. Adult Cattle
    • 10.1.1. Beef Cattle
    • 10.1.2. Dairy Cows
  • 10.2. Calves
    • 10.2.1. Beef Calves
    • 10.2.2. Dairy Calves
  • 10.3. Heifers

11. Bovine Respiratory Disease Treatment Market, by Distribution Channel

  • 11.1. Feed Mills
    • 11.1.1. Commercial Mills
    • 11.1.2. Onfarm Mills
  • 11.2. Online Pharmacies
    • 11.2.1. Animal Health Platforms
    • 11.2.2. General ERetail
  • 11.3. Veterinary Clinics
    • 11.3.1. Independent Clinics
    • 11.3.2. Large Practices

12. Bovine Respiratory Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bovine Respiratory Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bovine Respiratory Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Boehringer Ingelheim International GmbH
    • 15.3.3. Merck & Co., Inc.
    • 15.3.4. Elanco Animal Health Incorporated
    • 15.3.5. Ceva Sante Animale S.A.
    • 15.3.6. Virbac S.A.
    • 15.3.7. Phibro Animal Health Corporation
    • 15.3.8. Vetoquinol S.A.
    • 15.3.9. Dechra Pharmaceuticals PLC
    • 15.3.10. Bimeda Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BOVINE RESPIRATORY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BOVINE RESPIRATORY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BOVINE RESPIRATORY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, B